Japan’s generics sector set to grow

Genéricos/General | Posted 29/10/2010 post-comment0 Post your comment

Japan is currently the world’s second largest pharmaceutical market, with annual sales of approximately Yen 8,850 billion. Around 8% of its prescription drug sales (20% in sales volume) are generics.

picture02

By 2012, a combination of major drug patent expiries, a rapidly aging population and wide-ranging government initiatives to reduce healthcare spending will make the generic drug sector in Japan increasingly attractive. The Japanese government wants generics to reach more than 30% of the total pharmaceutical market in volume by 2012, doubling its position in early 2009.

A partnership between sanofi-aventis and Nichi-Iko could help the market grow, by promoting acceptance of generics. Mr Olivier Charmeil, Senior Vice President, Asia Pacific & Japan, sanofi-aventis, said “Our objective is to provide the Japanese generic market, which is expected to further expand in the future, with high quality and affordable pharmaceuticals, supporting the government's stated objective of increasing generic penetration.”

The move is the latest evidence of growing interest. Foreign companies already active in Japan's generic drugs market include Pfizer and Teva and the arrival of sanofi-aventis will increase the competitive pressure on smaller domestic suppliers. Japanese firm Daiichi Sankyo, the parent company of Ranbaxy, also decided to start manufacturing generics earlier this year.

Related articles

Ranbaxy to transfer R & D and focus on generics

Sanofi-aventis and Nichi-Iko announce joint venture for generics in Japan

Reference

Sanofi-aventis Press Release. Sanofi-aventis and Generics Leader Nichi-Iko to Establish New Joint Venture for Generics in Japan. 28 May 2010

comment icon Comments (0)
Post your comment
Related content
FDA closes Zhejiang Huahai Pharmaceutical warning letter
Application V15a16
Genéricos/General Posted 19/11/2021
FDA reaches 100 generic approvals
53 MD002445
Genéricos/General Posted 12/11/2021
New five-year medicines agreements in Australia
24-AA011041
Genéricos/General Posted 24/09/2021
Generics applications under review by EMA – July 2021
EMA logo 2 V13F14
Genéricos/General Posted 23/07/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010